Leerink Partners analyst Thomas Smith has maintained their bullish stance on IRON stock, giving a Buy rating on July 18.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Thomas Smith has given his Buy rating due to a combination of factors surrounding Disc Medicine’s strategic advancements and regulatory progress. The company has received positive feedback from the FDA regarding their lead asset, bitopertin, which is aimed at treating erythropoietic protoporphyria (EPP). This feedback has allowed Disc Medicine to narrow the timing for their New Drug Application (NDA) submission to October 2025, which is earlier than previously anticipated.
Furthermore, the company plans to utilize an accelerated approval pathway, which is expected to expedite the commercialization process and enhance the stock’s value. The alignment with the FDA on the submission timeline and the positive outcomes from clinical trials reinforce the potential for bitopertin to be the first drug to follow this regulatory path. These developments, along with upcoming data releases for other promising treatments, position Disc Medicine as a strong investment opportunity, making it one of the top picks for 2025.
Smith covers the Healthcare sector, focusing on stocks such as Disc Medicine, Sagimet Biosciences, Inc. Class A, and MoonLake Immunotherapeutics. According to TipRanks, Smith has an average return of 36.2% and a 52.85% success rate on recommended stocks.
In another report released on July 18, LifeSci Capital also maintained a Buy rating on the stock with a $85.00 price target.